Bank of New York Mellon’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-359,863
| Closed | -$3.38M | – | 4287 |
|
|
2020
Q3 | $3.38M | Sell |
359,863
-31,266
| -8% | -$297K | ﹤0.01% | 2416 |
|
|
2020
Q2 | $2.99M | Sell |
391,129
-6,416
| -2% | -$49.1K | ﹤0.01% | 2463 |
|
|
2020
Q1 | $2.46M | Sell |
397,545
-24,540
| -6% | -$216K | ﹤0.01% | 2454 |
|
|
2019
Q4 | $5.14M | Buy |
422,085
+4,058
| +1% | +$44.3K | ﹤0.01% | 2329 |
|
|
2019
Q3 | $4.83M | Sell |
418,027
-5,897
| -1% | -$62.1K | ﹤0.01% | 2306 |
|
|
2019
Q2 | $4.24M | Buy |
423,924
+12,063
| +3% | +$130K | ﹤0.01% | 2415 |
|
|
2019
Q1 | $5.3M | Sell |
411,861
-5,497
| -1% | -$81.9K | ﹤0.01% | 2306 |
|
|
2018
Q4 | $6.34M | Sell |
417,358
-1,863
| -0.4% | -$35.5K | ﹤0.01% | 2156 |
|
|
2018
Q3 | $8.38M | Buy |
419,221
+11,176
| +3% | +$254K | ﹤0.01% | 2127 |
|
|
2018
Q2 | $7.96M | Sell |
408,045
-12,880
| -3% | -$285K | ﹤0.01% | 2146 |
|
|
2018
Q1 | $8.48M | Sell |
420,925
-216,823
| -34% | -$3.67M | ﹤0.01% | 2069 |
|
|
2017
Q4 | $8.45M | Sell |
637,748
-71,391
| -10% | -$1.08M | ﹤0.01% | 2070 |
|
|
2017
Q3 | $13.1M | Sell |
709,139
-8,114
| -1% | -$151K | ﹤0.01% | 1842 |
|
|
2017
Q2 | $13.2M | Sell |
717,253
-7,944
| -1% | -$157K | ﹤0.01% | 1818 |
|
|
2017
Q1 | $16.4M | Buy |
725,197
+277,052
| +62% | +$6.63M | ﹤0.01% | 1663 |
|
|
2016
Q4 | $15.6M | Sell |
448,145
-22,770
| -5% | -$680K | ﹤0.01% | 1697 |
|
|
2016
Q3 | $11.5M | Sell |
470,915
-17,266
| -4% | -$432K | ﹤0.01% | 1800 |
|
|
2016
Q2 | $11.7M | Buy |
488,181
+460
| +0.1% | +$10.5K | ﹤0.01% | 1765 |
|
|
2016
Q1 | $11.4M | Buy |
487,721
+243,186
| +99% | +$5.77M | ﹤0.01% | 1757 |
|
|
2015
Q4 | $7.38M | Buy |
244,535
+56,451
| +30% | +$1.82M | ﹤0.01% | 1999 |
|
|
2015
Q3 | $7.47M | Buy |
188,084
+7,811
| +4% | +$485K | ﹤0.01% | 2013 |
|
|
2015
Q2 | $12.4M | Buy |
180,273
+29,256
| +19% | +$1.84M | ﹤0.01% | 1839 |
|
|
2015
Q1 | $8.25M | Buy |
151,017
+12,000
| +9% | +$572K | ﹤0.01% | 2042 |
|
|
2014
Q4 | $5.92M | Sell |
139,017
-21,358
| -13% | -$772K | ﹤0.01% | 2232 |
|
|
2014
Q3 | $5.12M | Buy |
160,375
+44,319
| +38% | +$945K | ﹤0.01% | 2306 |
|
|
2014
Q2 | $2.4M | Sell |
116,056
-3,594
| -3% | -$66.4K | ﹤0.01% | 2792 |
|
|
2014
Q1 | $2.31M | Sell |
119,650
-1,738
| -1% | -$36.9K | ﹤0.01% | 2786 |
|
|
2013
Q4 | $2.95M | Buy |
121,388
+2,556
| +2% | +$60.1K | ﹤0.01% | 2635 |
|
|
2013
Q3 | $2.55M | Buy |
118,832
+2,532
| +2% | +$59.8K | ﹤0.01% | 2691 |
|
|
2013
Q2 | $2.59M | Buy |
+116,300
| New | +$2.56M | ﹤0.01% | 2620 |
|
Bank of New York Mellon's AMAG Position: Q4 2020 in Review
Bank of New York Mellon sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 359,863 shares — an estimated $3.38M sold.
Bank of New York Mellon first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $16.4M in Q1 2017. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Bank of New York Mellon reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Bank of New York Mellon sold 359,863 AMAG Pharmaceuticals shares in Q4 2020, an estimated $3.38M.
- Bank of New York Mellon first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Bank of New York Mellon's AMAG Pharmaceuticals position peaked at $16.4M in Q1 2017.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Bank of New York Mellon's 13F filing for Q4 2020, filed 9 Feb 2021.